ATR and neoplasm: The model is calibrated with data generated in a BRCA-wild type HRD positive patient-derived xenograft (PDX) tumour model for PARP inhibitors rucaparib or talazoparib, the ATR inhibitor gartisertib [35, 36] and their combination.